A vaccine that prevents severe disease 70% of the time is very good.
For generations, parents of newborns have faced the arrival of winter with a particular dread — the knowledge that respiratory syncytial virus could send their infant to the hospital with no vaccine standing between them and that fate. Pfizer's phase 3 trial results now suggest that a single dose given to pregnant women may cross the placenta and shield newborns through their most fragile first months, with 82% effectiveness against severe illness in the first 90 days. The data, still awaiting peer review and FDA scrutiny, arrives amid a nationwide surge in pediatric RSV cases that has already strained hospital capacity to its limits. If approved, this would mark the first vaccine capable of protecting infants before they are old enough to receive one themselves.
- Hospitals across the country are buckling under a simultaneous surge of RSV, flu, and COVID in children — and right now, no RSV vaccine exists to blunt that wave.
- Pfizer's trial enrolled roughly 7,400 pregnant women and found that maternal vaccination could pass protective antibodies directly to the fetus, offering newborns a shield they cannot yet build for themselves.
- The 82% effectiveness against severe infant illness in the first 90 days is drawing cautious praise from infectious disease specialists, though experts note the protection fades and peer-reviewed publication has not yet followed the press release.
- An independent safety board recommended halting enrollment early — a signal that the evidence of benefit was strong enough that continuing a placebo arm was no longer ethically justifiable.
- Pfizer plans to submit data to the FDA by year's end, with CEO Albert Bourla projecting the vaccine could reach pregnant patients by late 2023 or early 2024 — potentially reshaping how pediatricians protect the youngest and most vulnerable infants.
Pfizer announced Tuesday that its experimental RSV vaccine, given to pregnant women, can protect newborns from severe respiratory illness during the months when they are most vulnerable — and for which no vaccine has ever existed. In a phase 3 trial of roughly 7,400 pregnant women, a single dose administered in the late second or third trimester produced antibodies that crossed the placenta, offering passive immunity at birth. The result: 82% effectiveness against severe RSV illness in the first 90 days of life, holding at 70% through six months.
The announcement lands at a fraught moment. Pediatric wards across the United States are already overwhelmed by a surge in RSV cases, compounded by flu and COVID. RSV is the leading cause of bronchiolitis and pneumonia in children under one, responsible for hundreds of infant deaths and thousands of hospitalizations each year. A vaccine that prevents severe disease in seven out of ten babies through their first half-year could meaningfully change that calculus.
Experts responded with measured optimism. Dr. Ofer Levy of Boston Children's Hospital called the results "very promising" while noting the data arrived as a press release rather than a peer-reviewed publication. Dr. Céline Gounder echoed that caution, calling 70% protection against severe disease "very good" while observing that the immunity appears to wane — raising the possibility that infants may eventually need their own booster dose.
Pfizer's RSVpreF vaccine uses established protein-targeting technology also found in hepatitis B and shingles vaccines. The company plans to submit its findings to the FDA by year's end, with potential availability by late 2023 or early 2024. Open questions remain — including whether the timing of vaccination during pregnancy affects protection — answers expected when full results reach a peer-reviewed journal. For now, the prospect of thousands of families spared a winter hospitalization feels, to those watching closely, like something worth waiting for.
Pfizer announced Tuesday that an experimental vaccine given to pregnant women can protect newborns from severe respiratory syncytial virus—a virus that sends thousands of infants to the hospital each year and for which no vaccine currently exists. In a phase 3 trial involving roughly 7,400 pregnant women, the vaccine demonstrated 82% effectiveness against severe RSV illness during a baby's first 90 days of life. That protection held at 70% through the first six months. The numbers are less impressive when measuring protection against any RSV infection—57% in the first three months, dropping to 51% by six months—but experts say the focus on severe disease is what matters most.
The trial worked by giving pregnant women a single dose of the vaccine during their late second or third trimester. Their bodies produced antibodies that crossed the placenta and entered the developing fetus, offering passive immunity at birth. Babies were then monitored for at least a year. The company plans to submit its data to the FDA by year's end, with CEO Albert Bourla telling investors the vaccine could reach patients by late 2023 or early 2024. An independent safety board monitoring the trial recommended halting enrollment early, citing the vaccine's demonstrated benefits.
The timing matters. Hospitals across the United States are currently overwhelmed with a surge in pediatric RSV cases, compounded by simultaneous waves of flu and COVID. RSV remains the leading cause of bronchiolitis and pneumonia in children under one year old, responsible for hundreds of deaths annually and thousands of hospitalizations. For infants, whose airways are still developing, the virus can cause severe breathing problems as mucus accumulates in the throat and lungs. A vaccine that prevents severe disease in seven out of ten babies through their most vulnerable first half-year could reshape how pediatricians approach this age group.
Dr. Ofer Levy, director of the Precision Vaccines Program at Boston Children's Hospital, called the results "very promising," though he cautioned that the announcement came only as a press release rather than peer-reviewed publication. "Obviously, we'd love it to be 100%," he said. "But many vaccines don't achieve that, so this is a very respectable level of efficacy." Dr. Céline Gounder, an infectious diseases specialist at KFF, was similarly measured: "A vaccine that prevents severe disease 70% of the time until the age of six months is very good." She noted the protection appears to fade over time, but if administered strategically, it could prevent substantial hospitalizations and deaths in infants.
One open question remains unanswered in the current data: whether the timing of maternal vaccination during pregnancy affects how much protection babies receive. Pfizer said that information will emerge when final results appear in a peer-reviewed journal. The company also noted that because babies are acquiring antibodies from their mothers rather than mounting their own immune response—a process called passive immunization—the protection may not last as long as active immunity would. This raises the possibility that infants could eventually need their own RSV vaccine dose, though Pfizer is not currently running trials in that population. The company plans to follow vaccinated mothers' babies for up to 24 months to gather more data.
Pfizer's vaccine, called RSVpreF, uses established technology found in hepatitis B and shingles vaccines, targeting a protein the virus uses to breach human cells. The company is also testing the same vaccine in older adults, who face their own risks from severe RSV, and reported positive results from that trial in August. Pfizer has signaled plans to eventually test the vaccine in younger age groups as well. For now, RSV joins flu, whooping cough, and COVID as vaccines recommended during pregnancy to protect infants from illness. Dr. William Schaffner of Vanderbilt University Medical Center imagined the relief such a tool could bring: "the thousands of parents that won't undergo the agony and distress of having their baby hospitalized." If the FDA approves and the vaccine reaches clinics as projected, that scenario could become routine within two years.
Citações Notáveis
A vaccine that prevents severe disease 70% of the time until the age of six months is very good.— Dr. Céline Gounder, infectious diseases specialist at KFF
This is a very respectable level of efficacy.— Dr. Ofer Levy, director of the Precision Vaccines Program at Boston Children's Hospital
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this vaccine is given to the mother rather than the baby directly?
Because the baby's immune system isn't fully developed yet. When the mother gets vaccinated, her body makes antibodies that cross into the baby through the placenta. The baby is born already protected—but it's borrowed protection, not the baby's own. That's why it fades over time.
So the protection won't last forever?
Right. The antibodies the mother passes down will eventually disappear from the baby's bloodstream. That's why experts think infants might eventually need their own RSV vaccine dose, though Pfizer hasn't tested that yet.
What makes RSV so dangerous for babies specifically?
Their airways are tiny and still developing. When RSV causes inflammation, mucus builds up quickly in those small passages. A baby can't clear it the way an older child or adult can. That's why RSV sends so many infants to intensive care units.
The efficacy numbers drop from 82% to 70% to 51%. Does that mean the vaccine is failing?
No—it depends on what you're measuring. Eighty-two percent against severe disease in the first three months is the critical number. Fifty-one percent against any infection is less impressive, but catching a mild cold is different from needing a hospital bed. Doctors care most about preventing the hospitalizations.
Why announce this now, before peer review?
The trial's independent safety board recommended stopping enrollment early because the results were strong enough. That's actually a sign the vaccine is working—they didn't want to give the placebo group a less effective option when a better one existed. But you're right to be cautious. We'll know more when the full data gets published and scrutinized.